RMD Financials ResMed

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated 28 h ago Overview →

Growth & profitability

Revenue has grown 11.7% per year over the past 5 years.
Net income has grown faster than revenue (17.6% vs 11.7% per year).
Operating margin has expanded, at 32.7% in the latest year.
Free cash flow has grown 18.6% per year over the past 5 years.

Financial health

The company holds more cash ($1.2B) than total debt ($668M).
Total debt has grown slower than revenue (-10.7% vs 11.7% per year).
Total debt is 0.4× EBITDA.

Shareholder returns

Dividends have been paid for 13 consecutive years, consuming 22.2% of earnings and 18.7% of free cash flow.
The dividend has grown 6.7% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
2025	$5.1B	$1.4B	59.4%	32.7%	$1.7B	$668M	$1.2B
2024	$4.7B	$1.0B	56.7%	28.2%	$1.3B	$707M	$238M
2023	$4.2B	$898M	55.8%	26.8%	$574M	$1.4B	$228M
2022	$3.6B	$779M	56.6%	28.0%	$216M	$775M	$274M
2021	$3.2B	$475M	57.5%	28.3%	$634M	$655M	$295M
2020	$3.0B	$622M	58.1%	27.4%	$707M	$1.2B	$463M
2019	$2.6B	$405M	57.3%	22.2%	$390M	$1.3B	$147M
2018	$2.3B	$316M	57.0%	23.2%	$442M	$281M	$189M
2017	$2.1B	$342M	58.1%	20.6%	$352M	$1.1B	$822M
2016	—	$352M	—	—	$489M	$1.2B	$731M
2015	—	$353M	—	—	—	$301M	$717M
2014	—	$345M	—	—	—	$301M	$906M
2013	—	$307M	—	—	$339M	$301M	$876M
2012	—	$255M	—	—	$336M	$251M	$810M
2011	—	$227M	—	—	$217M	$100M	$735M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	FCF	Total debt	Cash
Mar '26	$1.4B	$399M	62.2%	34.9%	$520M	$664M	$1.7B
Dec '25	$1.4B	$393M	61.8%	34.6%	$311M	$664M	$1.4B
Sep '25	$1.3B	$349M	61.5%	33.4%	$414M	$669M	$1.4B
Jun '25	$1.3B	$380M	60.8%	33.7%	$508M	$668M	$1.2B
Mar '25	$1.3B	$365M	59.3%	33.0%	$558M	$673M	$933M
Dec '24	$1.3B	$345M	58.6%	32.5%	$288M	$673M	$522M
Sep '24	$1.2B	$311M	58.6%	31.6%	$308M	$677M	$426M
Jun '24	$1.2B	$292M	58.5%	31.2%	$415M	$707M	$238M
Mar '24	$1.2B	$300M	57.9%	31.3%	$381M	$1.0B	$238M
Dec '23	$1.2B	$209M	55.6%	23.7%	$249M	$1.2B	$210M
Sep '23	$1.1B	$219M	54.4%	26.2%	$256M	$1.4B	$209M
Jun '23	$1.1B	$230M	55.0%	24.5%	$203M	$1.4B	$228M
Mar '23	$1.1B	$233M	55.3%	26.9%	$254M	$1.6B	$228M
Dec '22	$1.0B	$225M	56.1%	27.1%	$101M	$1.8B	$253M
Sep '22	$950M	$210M	56.9%	29.0%	$16M	$795M	$207M
Jun '22	$915M	$195M	57.1%	27.9%	$51M	$775M	$274M
Mar '22	$865M	$179M	56.8%	27.1%	$69M	$681M	$202M
Dec '21	$895M	$202M	56.4%	27.8%	$189M	$680M	$194M
Sep '21	$904M	$204M	56.0%	29.0%	-$93M	$806M	$276M
Jun '21	$876M	$195M	56.0%	27.6%	$199M	$655M	$295M

Valuation over time

How the market has priced RMD against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has fallen from 40.7× (Mar '23) to 20.6× (Jun '26).
The price-to-sales ratio has fallen from 8.9× (Mar '23) to 5.6× (Jun '26).
The dividend yield has risen from 0.8% (Mar '23) to 1.1% (Jun '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is RMD growing its revenue and profit?

Over the past 5 years, ResMed's revenue has grown 11.7% per year, and net income grown 17.6% per year. These are computed facts, not advice.

How much debt does RMD have?

As of FY2025, ResMed reported $668M of total debt against $1.2B of cash.

What is RMD's profit margin?

In FY2025, gross margin was 59.4%, operating margin 32.7%, and net margin 27.2%.

What is RMD's P/E ratio?

As of Jun '26, ResMed traded at a price-to-earnings ratio of about 20.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.